market access strategy

3.24.2014 Market Access

Patient-Reported Outcomes Spurred by Big Data in Pharma

By Nicole May, Research Analyst The opportunities are countless for Big Data in pharma, particularly within the clinical trial space.  Harnessing the data generated during clinical trials could help shorten trial timelines and lead to less expensive...
 

2.26.2014 Account Strategy for Payer Organizations

Provide a Framework for New Product Planning Groups to Influence Clinical Trials

By Jacob Presson, Research Analyst A common theme running through a lot of what we at Cutting Edge Information learn while conducting research on the pharmaceutical industry is the need for more consistent and productive communication between internal...
 

11.7.2013 Health Economics and Outcomes Research (HEOR)

HEORs and Tails: Why Is Staffing Market Access Teams So Difficult?

By Christie Shilling, Research Analyst Pharmaceutical market access teams hold a wide range of responsibilities and, as such, require employees with a variety of knowledge and skills.  Organizations that create a well-rounded market access team...
 

9.10.2013 Market Access

Product Pricing in Emerging Markets

By Yanis Saradjian, Director of Consulting In today’s global market, life science companies worldwide face challenges such as increased austerity measures, unfamiliar emerging markets payers and governments, greater emphasis on health economics...
 

8.6.2013 Account Strategy for Government

Government Affairs Teams: Promoting Patient Education and Access

By Sarah Ray, Research Analyst When it comes to healthcare in the US, the 10th annual National Healthcare Disparities Report — released earlier this year — shows that the quality of patient care is improving.  Yet when it comes to patient access,...
 

8.1.2013 Health Economics and Outcomes Research (HEOR)

Market Access Success: It’s All About Timing

By Natalie DeMasi, Research Analyst A good cook doesn’t just throw together all of the ingredients and hope everything turns out okay. Take a grilled cheese sandwich, for example. You melt butter before putting bread in a skillet, and you don’t...
 

7.3.2013 Account Strategy for Payer Organizations

Pharma Companies Make Market Access a Top Priority, With or Without Dedicated Departments

By Natalie DeMasi, Research Analyst As most companies’ main ambassadors to payers, market access groups lead the efforts to earn reimbursement for their organizations’ brands.  These groups specialize in working directly with payers — discussing...
 

5.23.2013 Market Access

New Survey: Market Access Trends in 2013

By Michelle Vitko, Senior Research Analyst In today’s pharmaceutical market, which is riddled with austerity measures and healthcare reform, securing favorable reimbursement rates is more difficult than ever.  Cutting Edge Information is kicking...
 

4.8.2013 Medical Affairs

Product Development Stage Dictates Medical Affairs Spending Patterns

Although marketing and market access functions may not support a developing drug until Phase 2 or even later, companies need to coordinate between several different teams as products move through different development stages beginning in the pre-clinical stage....
 

3.25.2013 Market Access

Pricing Troubles in India: Compulsory Licensing on the Subcontinent

Fresh news out of India this week is likely to add to pharmaceutical companies' concerns about pricing and sales in emerging markets.  Despite indications in February that compulsory licensing may be coming to an end, on March 18, BDR Pharmaceuticals applied for...